Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. (Q55462737)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076449%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076449%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076449%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Geric Maura

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076449%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Francois Ghiringhelli

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076449%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Veronique Lorgis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076449%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Guillaume Coppa

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076449%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Kahina Hassani

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076449%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Luc Taillandier

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076449%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Bruno Chauffert

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076449%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Sylvain Ladoire

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076449%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

11 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076449%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neuro-Oncology

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076449%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076449%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076449%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

351-358

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076449%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11060-011-0748-5

16 January 2020

exact match

0 references

cites work

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

Angiogenesis in brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

Antiangiogenic therapy of transgenic mice impairs de novo tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0748-5

High-dose antiangiogenic therapy for glioblastoma: less may be more?

21 January 2018

1 reference

12 December 2020

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

1 reference

12 December 2020

Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumour growth and angiogenesis in human glioblastoma xenografts

1 reference

12 December 2020

VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins

1 reference

12 December 2020

1 reference

12 December 2020

Quantitation of angiogenesis and its correlation with vascular endothelial growth factor expression in astrocytic tumors.

1 reference

12 December 2020

Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance.

1 reference

12 December 2020